Genovis AB (publ.) (STO:GENO)

Sweden · Delayed Price · Currency is SEK

21.25

0.00 (0.00%)

Dec 30, 2025, 5:29 PM CET

-13.27% (1Y)

Market Cap	1.40B
Revenue (ttm)	117.66M
Net Income (ttm)	21.18M
Shares Out	66.06M
EPS (ttm)	0.32
PE Ratio	65.83
Forward PE	46.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,869
Average Volume	151,566
Open	21.05
Previous Close	21.25
Day's Range	21.05 - 21.80
52-Week Range	17.10 - 30.45
Beta	2.13
RSI	57.47
Earnings Date	Feb 12, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 32

Stock Exchange Nasdaq Stockholm

Ticker Symbol GENO

Full Company Profile

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.

Financial Statements

News

Genovis AB (OSTO:GENO) Q3 2024 Earnings Report Preview: What to Expect

1 year ago - GuruFocus